Raphael Pharmaceutical Inc. financial data

Symbol
RAPH on OTC
Location
Las Vegas, NV
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.8% % -92%
Return On Assets -3569% % -548%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19,626,418 shares 4.9%
Common Stock, Shares, Outstanding 19,626,418 shares 4.9%
Entity Public Float $17,188,303 USD 72%
Common Stock, Value, Issued $196,000 USD 4.8%
Weighted Average Number of Shares Outstanding, Basic 19,626,418 shares 4.9%
Weighted Average Number of Shares Outstanding, Diluted 19,626,418 shares 4.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $497,000 USD 129%
General and Administrative Expense $888,000 USD 7.8%
Operating Income (Loss) $1,385,000 USD -33%
Nonoperating Income (Expense) $16,000 USD 24%
Net Income (Loss) Attributable to Parent $1,401,000 USD -32%
Earnings Per Share, Basic 0 USD/shares 100%
Earnings Per Share, Diluted 0 USD/shares 100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $20,000 USD -83%
Other Assets, Current $2,000 USD -78%
Assets, Current $5,000 USD -90%
Property, Plant and Equipment, Net $2,000 USD 0%
Assets $7,000 USD -86%
Accounts Payable, Current $125,000 USD 81%
Accrued Liabilities, Current $375,000 USD 1400%
Liabilities, Current $1,271,000 USD 91%
Retained Earnings (Accumulated Deficit) $9,895,000 USD -17%
Stockholders' Equity Attributable to Parent $1,264,000 USD -105%
Liabilities and Equity $7,000 USD -86%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $209,000 USD -22%
Net Cash Provided by (Used in) Financing Activities $240,000 USD 4.3%
Net Cash Provided by (Used in) Investing Activities $1,000 USD
Common Stock, Shares Authorized 50,000,000 shares 0%
Common Stock, Shares, Issued 19,626,418 shares 4.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $57,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,000 USD -92%
Deferred Tax Assets, Valuation Allowance $1,538,000 USD 21%
Deferred Tax Assets, Gross $1,538,000 USD 21%
Payments to Acquire Property, Plant, and Equipment $1,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $6,965,000 USD 21%